SN
Therapeutic Areas
Tarsus Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| XDEMVY (lotilaner ophthalmic solution) 0.25% | Demodex blepharitis | Approved |
| TP-03 (lotilaner ophthalmic solution) | Meibomian Gland Disease (MGD) | Phase 2b |
| TP-04 (topical lotilaner) | Papulopustular Rosacea | Phase 2a |
| TP-05 (oral lotilaner) | Lyme Disease Prevention | Phase 1 |
| TP-06 | Not Disclosed (Ophthalmic) | Preclinical |
| TP-07 | Not Disclosed (Dermatology) | Preclinical |
Leadership Team at Tarsus Pharmaceuticals
BA
Bobby Azamian
Chief Executive Officer, President, and Chairman of the Board
JF
Jeffrey Farrow
Chief Financial Officer
AM
Aziz Mottiwala
Chief Commercial Officer
MD
Michael D. Green
Chief Development Officer
VC
Vickie C. Driver
Chief Medical Officer
LM
Leonard M. Greenstein
General Counsel and Corporate Secretary
TY
Tachi Yamada
Board Director
JP
Jane P. Henderson
Board Director
BG
Brian G. Atwood
Board Director
LL
Laura L. Brege
Board Director